$321 Million is the total value of DAFNA Capital Management LLC's 75 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | AMYLYX PHARMACEUTICALS INC | $2,243,836 | – | 122,547 | +100.0% | 0.70% | – | |
New | THIRD HARMONIC BIO INC | $1,917,000 | – | 300,000 | +100.0% | 0.60% | – | |
CMPS | New | COMPASS PATHWAYS PLCsponsored ads | $1,428,200 | – | 193,000 | +100.0% | 0.44% | – |
CERE | New | CEREVEL THERAPEUTICS HOLDINGS INC | $1,357,826 | – | 62,200 | +100.0% | 0.42% | – |
IMGN | New | IMMUNOGEN INC | $1,317,210 | – | 83,000 | +100.0% | 0.41% | – |
GOSS | New | GOSSAMER BIO INC | $1,229,256 | – | 1,476,052 | +100.0% | 0.38% | – |
MGNX | New | MACROGENICS INC | $1,204,591 | – | 258,496 | +100.0% | 0.38% | – |
CGEM | New | CULLINAN ONCOLOGY INC | $1,151,920 | – | 127,284 | +100.0% | 0.36% | – |
IMVT | New | IMMUNOVANT INC | $863,775 | – | 22,500 | +100.0% | 0.27% | – |
New | ACELYRIN INC | $74,241 | – | 7,300 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
ATRICURE INC | 42 | Q3 2023 | 11.4% |
MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.